Carl Adams
Comptroller/Controller/Auditor bij TELEDYNE TECHNOLOGIES INCORPORATED
Profiel
Carl Adams is currently the Chief Audit Executive & Vice President at Teledyne Technologies, Inc. He previously worked as the Chief Financial Officer & Vice President at NeuroSigma, Inc. in 2014.
He completed his undergraduate degree at California State University-Northridge.
Actieve functies van Carl Adams
| Bedrijven | Functie | Begin |
|---|---|---|
| TELEDYNE TECHNOLOGIES INCORPORATED | Comptroller/Controller/Auditor | 01-12-2023 |
Eerdere bekende functies van Carl Adams
| Bedrijven | Functie | Einde |
|---|---|---|
NeuroSigma, Inc.
 NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Financieel Directeur/CFO | - |
Opleiding van Carl Adams
| California State University-Northridge | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| TELEDYNE TECHNOLOGIES INCORPORATED | Electronic Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Health Technology |